Aim: This study assessed the cost–utility of mogamulizumab, a novel monoclonal antibody,
versus established clinical management (ECM) in UK patients in previously treated
advanced mycosis fungoides (MF)/Sézary syndrome (SS). Materials & methods: Lifetime ...